- Key Takeaways
- Spravato claim denials fall into seven predictable root causes, including code-dose mismatches, expired prior authorizations, and incomplete REMS documentation filed after the session.
- A HHS OIG report found 13% of Medicare Advantage prior authorization denials met coverage rules, meaning a significant share of Spravato denials are preventable administrative failures, not clinical ones.
- Pre-submission checklist is a billing control requiring dose confirmation, active PA verification, benefit path confirmation, and timestamped 120-minute observation documentation before any claim is submitted.
- CMS prohibits billing G2082 or G2083 on new patient visits; first-session claims require a separate evaluation and management code or the G-code will be denied automatically.
- Denied Spravato claims can be appealed successfully when supported by the original Patient Monitoring Form, authorization confirmation, and a clinical summary submitted within payer deadlines.
Spravato (esketamine) now serves an estimated 2.8 million U.S. adults who qualify for treatment-resistant depression — roughly 31% of all medication-treated MDD patients, according to peer-reviewed analysis published in the Journal of Clinical Psychiatry. As more practices add the program, the billing errors following them are remarkably consistent.
The problem is not always clinical. A 2022 HHS Office of Inspector General report found that 13% of prior authorization denials in Medicare Advantage plans met Medicare coverage rules — meaning they were approved services that should never have been denied. When you apply that pattern to a drug with $600 or more in direct purchase cost per dose and a mandatory two-hour observation window per session, every avoidable denial is a direct hit to the practice’s cash position.
Neolytix has managed Spravato billing for psychiatric practices across the country, and the denial patterns repeat. Most Spravato claim denials are not random. They fall into a predictable set of seven root causes — and each one is preventable. If you are new to how the underlying billing architecture works, our Spravato billing and coding guide covers that foundation. This article focuses specifically on where claims fail after the billing process has started.
- Neolytix • Spravato Billing
Spravato Billing
Neolytix manages REMS compliance and buy-and-bill RCM as one integrated workstream, with NDC-specific claim workflows, PA expiration tracking, and contracted SLAs that keep denial rates below 5%.
1. Billing the Wrong Code for the Dose Administered
This is the most immediate cause of Spravato claim denials and one of the most common Spravato billing errors across new programs.
G2082 covers sessions with up to 56mg of esketamine. G2083 covers sessions above 56mg. These are not interchangeable, and payers cross-reference the administered dose against the billed code on every claim. A 56mg session billed under G2083 — or an 84mg session billed under G2082 — triggers an automatic mismatch denial, often with a “procedure inconsistent with billed service” remark code.
The same applies to unit counts under J0013 (the permanent HCPCS drug code effective January 2026, replacing S0013). J0013 is billed per 1mg increment. A 56mg session requires 56 units. A 28-unit claim for a 56mg session will be paid at half the drug reimbursement, if it is paid at all.
Prevention: Build a dose confirmation step into the billing trigger workflow. The administered dose documented in the clinical note must be matched against the G-code and unit count before claim submission, not after. For a full breakdown of the code logic, see Neolytix’s 2026 Spravato CPT and HCPCS code guide.
2. Missing or Late REMS Documentation
The FDA requires that Spravato be administered only in REMS-certified healthcare settings, with a Patient Monitoring Form (PMF) filed after each treatment session. The filing window is seven days from the date of service. Miss it, and the REMS record is incomplete.
Payers increasingly cross-reference REMS documentation when processing Spravato claims. A missing PMF does not always produce an immediate denial — but it creates a compliance gap that surfaces during claims audits, retrospective reviews, and prior authorization renewals. When a payer requests REMS records to support a PA renewal and the documentation is incomplete, the renewal fails, and all sessions billed without active authorization become denied.
Beyond billing, sustained REMS non-compliance puts the practice’s drug ordering access at risk entirely. The FDA and Janssen can deactivate a healthcare setting’s REMS certification for documentation failures.
Prevention: Treat PMF filing as a billing prerequisite, not an administrative afterthought. The safest operational model is to cross-reference every clinical session against the REMS portal before the corresponding claim is submitted.
3. Prior Authorization That Is Vague, Expired, or Missing Entirely
Prior authorization is the leading source of Spravato claim denials in commercial payer lines. The failure usually falls into one of three patterns: the PA was never initiated before treatment began, the clinical documentation submitted was too generic to meet payer-specific criteria, or the authorization expired mid-treatment and billing continued on the lapsed auth.
Most commercial payers require documented failure of at least two prior antidepressant trials, confirmed TRD or MDD-SIBA diagnosis, and REMS enrollment confirmation as minimum PA criteria. Generic language — “patient has treatment-resistant depression” — routinely fails. Payers want specific trial names, duration, and discontinuation reasons. Some payers apply additional step therapy requirements or restrict coverage to certain diagnosis codes, and a PA approved for F32.2 may not cover F33.2 even when the clinical picture is the same.
Authorization periods are also shorter than most practices expect. Many commercial plans authorize four to eight sessions before requiring renewal. A practice running a maintenance-phase patient through weekly sessions on a four-session authorization that expired three weeks ago is billing into a denial wall.
Prevention: PA should be initiated before the first session, not concurrently or after. Build payer-specific documentation packages and track authorization session counts actively. For broader context on how prior authorization failures affect revenue across service lines, our prior authorization guide covers the mechanics. For Spravato-specific PA management, our Spravato billing services team handles initiation, renewal, and appeals as part of an integrated workflow.
4. Split-Billing Confusion Between the Pharmacy and Medical Benefit
Spravato can route through either the medical benefit (buy-and-bill) or the pharmacy benefit (assignment of benefits), depending on the payer and the practice’s enrollment model. When billing staff apply buy-and-bill codes to a patient whose coverage routes through the pharmacy benefit — or vice versa — the claim is denied with a benefit-mismatch remark.
This is particularly common in practices that onboard new patients without confirming the benefit path at verification. Commercial payers and Medicare Advantage plans do not follow the same routing rules, and some payers have changed their Spravato coverage tiers since 2024. A patient whose plan approved buy-and-bill in 2024 may have been moved to a pharmacy benefit pathway in 2025 during plan renewals, without any notification to the practice.
Prevention: Benefits verification for Spravato must explicitly confirm the benefit path — medical or pharmacy — at every patient onboarding and at the start of each calendar year. Do not assume continuity from the prior year.
5. Visits Flagged as Not Medically Necessary
Not all Spravato denials are coding errors. Some are medical necessity denials, and they tend to cluster at two points: the transition from induction to maintenance phase, and sessions that deviate from the FDA-approved dosing schedule.
The FDA-approved Spravato dosing schedule begins with twice-weekly sessions for the first four weeks, transitions to weekly sessions for weeks five through eight, and then moves to weekly or every-two-weeks maintenance. Payers that apply clinical criteria strictly will deny sessions that fall outside this schedule — not because the treatment is wrong, but because the documented clinical rationale for the deviation is missing. A patient who needed an extra induction session due to a missed dose or adverse event has a defensible case. That defense, however, has to be in the chart and in the claim.
Similarly, as patients enter maintenance, some payers require renewed documentation of ongoing treatment response and continued medical necessity at each authorization renewal. Practices that auto-renew PAs without updated clinical summaries find that renewals are denied — and that retroactive claims for sessions already administered are denied alongside them.
Prevention: Documentation of clinical rationale for any schedule deviation must be explicit in the clinical note. For a reference on what payers expect in terms of session-level justification and reimbursement thresholds, see our Spravato reimbursement rates guide.
6. Observation Period Logged at Less Than 120 Minutes
Every Spravato session requires a minimum two-hour post-administration observation period. This is not a billing convention — it is an FDA REMS requirement, and it is bundled into the G2082 and G2083 reimbursement. CMS and most commercial payers consider the 120-minute observation to be part of what the G-code payment covers.
What triggers a denial is documentation that logs the observation at less than 120 minutes. A note recording “patient monitored for approximately 90 minutes and tolerated well” — even when the actual observation was longer — creates a documentation gap that payers use to reclassify the session as incomplete and reduce or deny payment.
Some practices also inadvertently create this problem by logging check-in and check-out times that, when calculated, fall short of 120 minutes due to intake processing delays. If the clinical documentation does not clearly show 120 or more minutes of post-dose monitoring, the claim is vulnerable.
Prevention: The observation start time and end time must be explicitly documented in every session note — not estimated, not approximate. Staff should record these as discrete timestamped fields, not narrative language.
7. G2082 or G2083 Billed for a New Patient Visit
This is one of the more technical Spravato billing errors, and it often catches practices by surprise. CMS rules prohibit billing G2082 or G2083 on a new patient visit. These codes apply only to established patients. A first-time Spravato session — where the patient is new to the practice, not just new to the drug — requires a separate evaluation and management code instead, not a G-code.
The error typically occurs when a practice begins a patient’s first Spravato session on the same date as their initial psychiatric evaluation. The billing staff, seeing that a Spravato session occurred, assigns G2082 or G2083. The payer, seeing a new patient flag, denies the G-code claim.
Some practices compound the error by also attempting to bill a concurrent E/M visit alongside G2082 or G2083 on an established-patient session. CMS bundles physician supervision into the G-code payment; separate E/M billing on the same date for the same provider is not payable.
Prevention: Build a new-versus-established patient check into the Spravato billing workflow. First sessions for new patients should be coded separately, and the established patient designation should be confirmed before any G-code is assigned.
Prevention Checklist: Before Every Claim
A pre-submission checklist addresses most of the seven denial causes above. Verify the following on every Spravato claim before submission:
- Dose confirmed and G-code matches (G2082 for ≤56mg, G2083 for >56mg)
- J0013 unit count matches administered milligrams
- PMF filed in REMS portal within seven days of the session
- Active PA on file and session count within the authorized range
- Benefit path confirmed (medical vs. pharmacy benefit)
- Observation period documented as 120 minutes or more with explicit start and end timestamps
- New vs. established patient status confirmed before any G-code is assigned
If a claim fails despite these checks, document the denial reason code and initiate an appeal with the supporting clinical record within 30 days. Most Spravato billing appeals that succeed do so with the original PMF, the authorization confirmation, and a clinical summary — not just a corrected claim.
Conclusion
Spravato claim denials are not inevitable. The majority trace back to documentation gaps, benefit path mismatches, and authorization failures — all of which can be caught before a claim is submitted rather than discovered after. For practices managing five or more active Spravato patients, the volume of pre-submission verification required exceeds what most internal billing workflows are built to handle.
Neolytix manages REMS compliance and RCM as a single integrated program for Spravato practices, with a target denial rate under 5% and a 98%+ first-pass rate on Spravato-coded claims. If your current denial rate is running higher than that, our Spravato billing team can complete a no-cost revenue audit to identify where the losses are occurring. You can also review how we handled a comparable challenge in behavioral health RCM in our behavioral health A/R recovery case study.
- Neolytix • Contact Us
Schedule a Consultation
Neolytix partners with healthcare organizations across revenue cycle, credentialing, and administrative operations ,14+ years of expertise and AI-enabled automation to reduce inefficiencies and drive sustainable growth.
Sources
U.S. Department of Health and Human Services, Office of Inspector General. “Some Medicare Advantage Organization Denials of Prior Authorization Requests Raise Concerns About Beneficiary Access to Medically Necessary Care.” April 2022. https://oig.hhs.gov/reports/all/2022/some-medicare-advantage-organization-denials-of-prior-authorization-requests-raise-concerns-about-beneficiary-access-to-medically-necessary-care/
U.S. Food and Drug Administration. Spravato (esketamine) REMS Program. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211243Orig1s000REMS.pdf
National Institute of Mental Health. Major Depression. https://www.nimh.nih.gov/health/statistics/major-depression
Zhdanava M, et al. “The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States.” Journal of Clinical Psychiatry, 2021. Referenced via: https://pmc.ncbi.nlm.nih.gov/articles/PMC11008705/
Frequently Asked Questions
Can a Spravato claim be appealed after a not-medically-necessary denial?
Yes. Not-medically-necessary denials are among the most successfully appealed denial types, provided the appeal includes specific clinical documentation — the patient’s antidepressant trial history, REMS enrollment confirmation, the treating provider’s rationale, and any REMS monitoring records from the session in question. Appeals submitted without this supporting documentation almost always fail regardless of whether the underlying clinical case is valid.
What remark codes typically appear on a denied Spravato claim?
The most common are CO-4 (procedure inconsistent with modifier or billed service), CO-97 (service bundled into another payment), CO-167 (diagnosis not covered), and CO-15 or CO-57 (prior authorization missing or not obtained). CO-4 usually signals a code-dose mismatch. CO-97 often flags an unbundling error — an E/M billed alongside a G-code. CO-167 points to a diagnosis code that does not match the payer’s covered indications for Spravato.
Do Medicare and commercial payers apply the same criteria when reviewing Spravato claims?
No. Medicare (traditional) and Medicare Advantage plans follow different coverage rules. Traditional Medicare applies national coverage determinations and CMS coding guidelines directly. Medicare Advantage plans set their own clinical criteria and prior authorization requirements, which can be more restrictive. Commercial plans vary further by payer and sometimes by product line within the same payer. Payer-specific verification is necessary at patient onboarding and at any plan renewal.
What is the deadline to appeal a denied Spravato claim?
Deadlines vary by payer. Medicare claims must generally be appealed within 120 days of the denial notice. Commercial payer deadlines typically range from 30 to 180 days, depending on the plan’s contract terms. Missing the appeal window permanently forfeits the revenue on that claim, so tracking denial dates alongside appeal deadlines is a required part of any Spravato A/R management process.
